Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 277 matching drugs for HDAC6 — including drugs targeting any of its 17 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC6 Direct 2
pharmacological study, romidepsin HDAC6 Direct 2
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC6 Direct 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC6 Direct 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab HDAC6 Direct 1
bevacizumab, temozolomide, vorinostat HDAC6 Direct 1
capecitabine, vorinostat, radiotherapy, surgery to remove tumor HDAC6 Direct 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff HDAC6 Direct 1
laboratory biomarker analysis, pharmacological study, temozolomide, vorinostat HDAC6 Direct 1
pembrolizumab, vorinostat, temozolomide, radiotherapy HDAC6 Direct 1
romidepsin HDAC6 Direct yes 1
romidepsin, azacitidine, nab-paclitaxel, gemcitabine, durvalumab, lenalidomide capsule HDAC6 Direct 1
romidepsin, laboratory biomarker analysis HDAC6 Direct 1
vorinostat, bevacizumab HDAC6 Direct 1
vorinostat, bevacizumab, irinotecan HDAC6 Direct 1
vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis HDAC6 Direct 1
vorinostat, conventional surgery HDAC6 Direct 1
vorinostat, temozolomide, diagnostic laboratory biomarker analysis, pharmacological study HDAC6 Direct 1
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration HDAC6 Direct 1
vorinostat, therapeutic conventional surgery, bortezomib HDAC6 Direct 1
belinostat HDAC6 Direct yes 0
panobinostat HDAC6 Direct yes 0
panobinostat lactate HDAC6 Direct yes 0
vorinostat HDAC6 Direct yes 0
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib CDK6 SSL via CDK6 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR3 SSL via FGFR3 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PIK3CA SSL via PIK3CA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib SMO SSL via SMO 3
afatinib ERBB2 SSL via ERBB2 yes 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR3 SSL via FGFR3 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
pembrolizumab, belzutifan, lenvatinib FGFR3 SSL via FGFR3 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
abemaciclib CDK6 SSL via CDK6 yes 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR3 SSL via FGFR3 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel IGF1R SSL via IGF1R 2
alvocidib, paclitaxel CDK6 SSL via CDK6 2
bbi-355, erlotinib, futibatinib FGFR3 SSL via FGFR3 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib CDK6 SSL via CDK6 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study IGF1R SSL via IGF1R 2
cixutumumab, laboratory biomarker analysis, paclitaxel, pharmacological study IGF1R SSL via IGF1R 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab CDK6 SSL via CDK6 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
entinostat HDAC1 SSL via HDAC1 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC1 SSL via HDAC1 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC2 SSL via HDAC2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR3 SSL via FGFR3 2
lapatinib ERBB2 SSL via ERBB2 yes 2
lenvatinib, pembrolizumab FGFR3 SSL via FGFR3 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FGFR3 SSL via FGFR3 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FGFR3 SSL via FGFR3 2
motexafin gadolinium, radiation therapy RRM2 SSL via RRM2 2
nintedanib FGFR3 SSL via FGFR3 yes 2
nintedanib, pembrolizumab FGFR3 SSL via FGFR3 2
palbociclib CDK6 SSL via CDK6 yes 2
pazopanib FGFR3 SSL via FGFR3 yes 2
pembrolizumab, guadecitabine, mocetinostat HDAC1 SSL via HDAC1 2
pembrolizumab, guadecitabine, mocetinostat HDAC2 SSL via HDAC2 2
pembrolizumab, lenvatinib FGFR3 SSL via FGFR3 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FGFR3 SSL via FGFR3 2
pembrolizumab, sonidegib SMO SSL via SMO 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FGFR3 SSL via FGFR3 2
pharmacological study, romidepsin HDAC1 SSL via HDAC1 2
pharmacological study, romidepsin HDAC2 SSL via HDAC2 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FGFR3 SSL via FGFR3 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 SSL via ERBB2 2
trastuzumab ERBB2 SSL via ERBB2 yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 SSL via ERBB2 2
trastuzumab, tipifarnib ERBB2 SSL via ERBB2 2
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 SSL via ERBB2 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC1 SSL via HDAC1 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC1 SSL via HDAC1 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat HDAC2 SSL via HDAC2 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide RRM2 SSL via RRM2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 SSL via ERBB2 1
abemaciclib, abemaciclib CDK6 SSL via CDK6 1
abemaciclib, bevacizumab CDK6 SSL via CDK6 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf CDK6 SSL via CDK6 1
abemaciclib, ly3023414, gemcitabine, capecitabine CDK6 SSL via CDK6 1
abemaciclib, ly3214996 CDK6 SSL via CDK6 1
abemaciclib, surgery CDK6 SSL via CDK6 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy HDAC1 SSL via HDAC1 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy HDAC2 SSL via HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid HDAC1 SSL via HDAC1 1
adriamycin, cyclophosphamide, vindesine, valproic acid HDAC2 SSL via HDAC2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib CDK6 SSL via CDK6 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 SSL via ERBB2 1
afatinib, docetaxel, radiation therapy ERBB2 SSL via ERBB2 1
afatinib, gefitinib ERBB2 SSL via ERBB2 1
afatinib, irinotecan ERBB2 SSL via ERBB2 1
alpelisib, everolimus, exemestane PIK3CA SSL via PIK3CA 1
alvocidib, docetaxel CDK6 SSL via CDK6 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis CDK6 SSL via CDK6 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib CDK6 SSL via CDK6 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.